We are pioneering IgY-based antibody therapeutics to revolutionize the treatment of liver diseases through microbiome modulation. Our cutting-edge research and technology harness the unique properties of avian-derived antibodies to selectively neutralize harmful microbial components while preserving beneficial gut flora. By targeting the gut-liver axis, we aim to develop first-in-class, non-invasive therapies that address the root causes of alcohol-associated hepatitis (AH).

Gut – Liver Axis

The gut-liver axis forms a critical connection between the digestive system and liver health. The liver is the first organ encountered after gut content absorption via the portal vein, exposing it to microbial metabolites, toxins, and nutrients. In turn, the liver regulates gut homeostasis by producing bile acids, Immunoglobulin A (IgA), and antimicrobial molecules.